Physician profile
Albert C Brown
NPI 1174516744
$4,891.11
in general payments reported to CMS, 2019-2025
28 companies · $21.74 in 2025
The $21.74 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $779 · 2021: $1,015 · 2022: $1,219 · 2023: $952 · 2024: $163 · 2025: $21.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.98 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $818.89 | 2019-2024 | Otezla, Repatha |
| Abbvie INC. | $773.23 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $715.21 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $426.26 | 2021-2023 | |
| Astellas Pharma US INC | $262.98 | 2019-2023 | Myrbetriq, Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $211.79 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $200.63 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $196.17 | 2019-2023 | Farxiga, Breztri |
| Sunovion Pharmaceuticals INC. | $190.30 | 2019 | |
| Lilly USA, LLC | $162.29 | 2020-2023 | Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.55 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $146.58 | 2019-2022 | |
| Glaxosmithkline, LLC. | $95.27 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $86.33 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.75 | 2021-2023 | Trintellix |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $65.78 | 2019-2023 | |
| Sanofi Pasteur INC. | $44.39 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $39.11 | 2020 | |
| Novartis Pharmaceuticals Corporation | $37.95 | 2019-2021 | |
| Esperion Therapeutics, INC. | $37.06 | 2021 | |
| Pacira Therapeutics, INC. | $25.38 | 2019 | |
| Allergan, INC. | $24.76 | 2020 | |
| Axsome Therapeutics, INC. | $22.63 | 2023 | Auvelity |
| Exact Sciences Corporation | $21.69 | 2023 | Cologuard Collection Kit |
| Endo Pharmaceuticals INC. | $19.23 | 2019 | |
| Neurocrine Biosciences, INC. | $13.64 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.48 | 2019 | |
| Alkermes, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.